Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

605 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity.
van Steenbrugge GJ, van Uffelen CJ, Bolt J, Schröder FH. van Steenbrugge GJ, et al. Among authors: schroder fh. J Steroid Biochem Mol Biol. 1991;40(1-3):207-14. doi: 10.1016/0960-0760(91)90184-7. J Steroid Biochem Mol Biol. 1991. PMID: 1958522 Review.
Prostate cancer.
Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS. Attard G, et al. Among authors: schroder f. Lancet. 2016 Jan 2;387(10013):70-82. doi: 10.1016/S0140-6736(14)61947-4. Epub 2015 Jun 11. Lancet. 2016. PMID: 26074382 Review.
The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.
Schröder F, Kattan MW. Schröder F, et al. Eur Urol. 2008 Aug;54(2):274-90. doi: 10.1016/j.eururo.2008.05.022. Epub 2008 May 22. Eur Urol. 2008. PMID: 18511177 Review.
Who and when should we screen for prostate cancer? Interviews with key opinion leaders.
Carlsson S, Leapman M, Carroll P, Schröder F, Albertsen PC, Ilic D, Barry M, Frosch DL, Vickers A. Carlsson S, et al. Among authors: schroder f. BMC Med. 2015 Nov 27;13:288. doi: 10.1186/s12916-015-0526-x. BMC Med. 2015. PMID: 26612204 Free PMC article.
Prostate cancer screening in Europe - Authors' reply.
Schröder F, Hugosson J, Carlsson S, Moss S, Roobol M, Auvinen A. Schröder F, et al. Lancet. 2015 Apr 18;385(9977):1507-8. doi: 10.1016/S0140-6736(15)60749-8. Lancet. 2015. PMID: 25933276 No abstract available.
Screening: should more biopsies be taken in larger prostates?
van Leeuwen P, van den Bergh R, Wolters T, Schröder F, Roobol M. van Leeuwen P, et al. Among authors: schroder f. BJU Int. 2009 Oct;104(7):919-24. doi: 10.1111/j.1464-410X.2009.08627.x. Epub 2009 May 18. BJU Int. 2009. PMID: 19466943 Clinical Trial.
Active surveillance for low-risk prostate cancer.
Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A, Trock BJ, Valdagni R. Bangma CH, et al. Among authors: schroder fh. Crit Rev Oncol Hematol. 2013 Mar;85(3):295-302. doi: 10.1016/j.critrevonc.2012.07.005. Epub 2012 Aug 9. Crit Rev Oncol Hematol. 2013. PMID: 22878262 Review.
Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J. van Leeuwen PJ, et al. Among authors: schroder fh. Eur Urol. 2012 Jan;61(1):171-6. doi: 10.1016/j.eururo.2011.08.002. Epub 2011 Aug 10. Eur Urol. 2012. PMID: 21840117 Clinical Trial.
Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Vis AN, Schröder FH. Vis AN, et al. Among authors: schroder fh. BJU Int. 2009 Nov;104(9):1191-7. doi: 10.1111/j.1464-410X.2009.08743.x. Epub 2009 Jul 14. BJU Int. 2009. PMID: 19624596 Review.
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN, Schröder FH. Vis AN, et al. Among authors: schroder fh. BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. BJU Int. 2009. PMID: 19558559 Review.
605 results
Jump to page